-
Guangzhou Pharma and BioCubaFarma Chart New Course with Joint Biologics R&D and Exchange Deal
•
Guangzhou Pharmaceutical Holdings Ltd., a prominent player in China’s pharmaceutical sector, has inked a strategic letter of intent with BioCubaFarma, Cuba’s foremost state-owned pharmaceutical juggernaut, to embark on a joint venture in research and development (R&D), manufacturing, and commercialization of avant-garde pharmaceutical products within the Chinese market, with a spotlight…
-
LanssonPharm Secures Series A Funding to Accelerate CNS Drug Development
•
LanssonPharm, a company dedicated to the development of central nervous system (CNS) drugs, has announced the completion of a Series A funding round worth tens of millions of yuan. The financing was led by Yipu Capital, with follow-on investments from Qianrong Capital and existing shareholder Northern Light Venture Capital. This…
-
China’s Ministry of Health Tightens Organ Transplant Regulations with Expert Conference
•
Shi Bingyi, a distinguished Member of the National Committee of the CPPCC (Chinese People’s Political Consultative Conference) and Director of the Organ Transplantation Center of the People’s Liberation Army (PLA), has disclosed that China’s Ministry of Health has convened a panel of 70 experts to rigorously assess hospitals involved in…
-
China Launches Unprecedented Multi-Center Hypertension Study with Global Implications
•
On April 2nd, a landmark healthcare initiative, the “Hypertension Prevention and Treatment Research” project, commenced in Beijing with the backing of China’s Ministry of Health (MOH) and Ministry of Science and Technology (MOST). This ambitious project is structured as a multi-center clinical trial, encompassing 150 clinical centers and engaging 13,000…
-
China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments
•
China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a remarkable leap in its financial results for 2006 on April 2nd. The company reported a staggering 216% increase in total revenues, surging from US$380,519 in 2005 to US$1.2 million in 2006. This revenue growth was…
-
Shanghai to Launch China’s Largest ADR Database, Enhancing Pharmaceutical Oversight
•
Shanghai is advancing towards a significant milestone in pharmaceutical safety with plans to establish the largest adverse drug reaction (ADR) database in China. The nascent database has already amassed nearly 300,000 personal drug files and an excess of 10,000 ADR reports, providing a robust foundation for the project. The “Setting…
-
China Unveils TCM Development Guidelines: A Strategic Defense of Traditional Medicine
•
In a strategic move to assert the value and historical significance of Traditional Chinese Medicine (TCM), China’s Ministry of Health, in conjunction with 15 other government departments, has issued the “Traditional Chinese Medicine Innovation & Development Guidelines from 2006 to 2020” in March. These comprehensive guidelines are seen as a…
-
India Launches Anti-Dumping Campaign Against Chinese Vitamin B12 and Ceftriaxone Sodium Producers
•
In a strategic response to India’s Ministry of Commerce and Industry’s (MOFCOM) anti-dumping ruling against Chinese vitamin A palmitate producers, Indian pharmaceutical firms have initiated a new campaign on March 13. This time, the focus is on China’s manufacturers of vitamin B12 and ceftriaxone sodium, with customs codes 29362610 and…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
